Valuation

NRIXNurix Therapeutics Inc

StockNasdaqUnited StatesHealth careEU retail investors: available

+5.5% today · +31.1% over a year

2/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 94% of the instruments we score

Quality: among the best of its peers; priced lower than most peers. No dividend.

Nurix Therapeutics Inc (NRIX) valuation against sector peers: P/E 6.0 (sector median 30.9), P/B 1.8, EV/EBIT 3.6, free-cash-flow yield 21.0%, P/S 2.5.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricNRIXSector medianvs median
P/E6.030.9 · n=15981% below
P/B1.84.0 · n=30754% below
P/S2.54.1 · n=29939% below
EV/EBIT3.625.6 · n=14686% below
Free-cash-flow yield21.0%1.4% · n=2881,351% above
Dividend yield0.00%0.00% · n=362—
Return on equity44.0%−2.1% · n=308—
Return on invested capital106.9%0.6% · n=28216,485% above
Gross margin—63.3% · n=205—
Net debt / EBITDA−2.411.27 · n=151291% below

Value factor: 96 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co48.233.0—1.5%0.6%6/10
JNJJohnson & Johnson42.28.3—3.0%1.9%8/10
ABBVAbbVie50.3—27.73.6%2.9%6/10
MRKMerck149.58.2—4.0%2.3%8/10
UNHUnitedHealth22.43.417.16.4%2.3%10/10
TMOThermo Fisher Scientific37.84.935.72.8%0.3%9/10
AMGNAmgen26.817.523.23.8%2.1%8/10
GILDGilead Sciences—16.1—6.6%1.9%5/10
ABTAbbott40.73.832.93.5%2.8%6/10
PFEPfizer41.31.9—7.1%7.4%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 31 Aug 2026 · filed 13 Oct 2026